X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Descartes-08 is a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). It is under phase 2 clinical development for the treatment of generalized myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Product Name: Descartes-08
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Product Name: Descartes-08
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Selecta Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 13, 2023
Details:
This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory diseases.
Lead Product(s): RNA Engineered Allogeneic Human Mesenchymal Stem Cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Descartes-30
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 04, 2021
Details:
Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies.
Lead Product(s): Descartes-11
Therapeutic Area: Oncology Product Name: Descartes-11
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
The Phase 1/2 clinical trial is the first-in-human study which aims to determine the safety and preliminary efficacy of Descartes-30 in patients with moderate to severe ARDS.
Lead Product(s): Descartes 30
Therapeutic Area: Infections and Infectious Diseases Product Name: Descartes 30
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
